Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
71
NVZMY Quote, Financials, Valuation and Earnings
Last price:
$59.77
Seasonality move
:
6.76%
Day range:
$58.79 - $61.45
52-week range:
$49.90 - $75.99
Dividend yield:
1.72%
P/E ratio:
42.46x
P/S ratio:
5.93x
P/B ratio:
2.46x
Volume:
49.9K
Avg. volume:
176K
1-year change:
1.79%
Market cap:
$27.7B
Revenue:
$4.7B
EPS (TTM):
$1.40
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Novonesis (Novozymes A/S) has -- downside to fair value with a price target of -- per share.
NVZMY vs. S&P 500
-
Over the past 5 trading days, Novonesis (Novozymes A/S) has overperformed the S&P 500 by 0.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novonesis (Novozymes A/S) does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novonesis (Novozymes A/S) has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Novonesis (Novozymes A/S) reported revenues of $1.2B.
Earnings Growth
-
Novonesis (Novozymes A/S) has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Novonesis (Novozymes A/S) reported earnings per share of $0.30.
Enterprise value:
31B
EV / Invested capital:
--
Price / LTM sales:
5.93x
EV / EBIT:
31.94x
EV / Revenue:
6.61x
PEG ratio (5yr expected):
0.45x
EV / Free cash flow:
36.49x
Price / Operating cash flow:
32.72x
Enterprise value / EBITDA:
18.83x
Gross Profit (TTM):
$2.5B
Return On Assets:
3.56%
Net Income Margin (TTM):
13.96%
Return On Equity:
5.31%
Return On Invested Capital:
4.28%
Operating Margin:
18.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $2.6B | $4.1B | $4.7B | $1B | $1.2B | |
| Gross Profit | $1.4B | $2B | $2.5B | $529M | $650.3M | |
| Operating Income | $645M | $688.6M | $971.6M | $186.8M | $210.3M | |
| EBITDA | $846.4M | $1.3B | $1.6B | $353.6M | $416M | |
| Diluted EPS | $1.58 | $0.72 | $1.40 | $0.20 | $0.30 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1.3B | $1.4B | $1.9B | $2.3B | |
| Total Assets | $3.9B | $4B | $4.2B | $16.8B | $20.5B | |
| Current Liabilities | $867.4M | $999.3M | $1.1B | $1.1B | $3.2B | |
| Total Liabilities | $2B | $2B | $2.1B | $5.2B | $7.7B | |
| Total Equity | $1.9B | $2B | $2.1B | $11.6B | $12.7B | |
| Total Debt | $635.9M | $578.4M | $696.2M | $1.6B | $1.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $602.4M | $1.1B | $1.4B | $252.5M | $377.2M | |
| Cash From Investing | -$309.5M | -$310.6M | -$2.2B | -$110.5M | -$266.9M | |
| Cash From Financing | -$274.1M | -$671.4M | $853.4M | -$130.5M | -$110.5M | |
| Free Cash Flow | $304.1M | $717.9M | $850.5M | $106.7M | $118.9M | |
NVZMY
Sector
Market Cap
$27.7B
$23.6M
Price % of 52-Week High
78.66%
62.93%
Dividend Yield
1.72%
0%
Shareholder Yield
0.76%
-3.93%
1-Year Price Total Return
1.79%
14.68%
Beta (5-Year)
1.057
0.610
Dividend yield:
1.72%
Annualized payout:
$0.96
Payout ratio:
136.53%
Growth streak:
1 years
Technicals
8-day SMA
Buy
Level
$58.64
200-day SMA
Sell
Level
$63.18
Bollinger Bands (100)
Sell
Level
57.83 - 64.35
Chaikin Money Flow
Buy
Level
8.9M
20-day SMA
Buy
Level
$56.12
Relative Strength Index (RSI14)
Buy
Level
61.12
ADX Line
Buy
Level
19.74
Williams %R
Sell
Level
-14.5455
50-day SMA
Buy
Level
$58.97
MACD (12, 26)
Buy
Level
0.31
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
6.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.537)
Buy
CA Score
(Annual)
Level (0.5752)
Buy
Beneish M-Score
(Annual)
Level (-2.6496)
Sell
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.8543)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novonesis (Novozymes A/S) engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.
Stock Forecast FAQ
In the current month, NVZMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVZMY average analyst price target in the past 3 months is --.
-
Where Will Novonesis (Novozymes A/S) Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novonesis (Novozymes A/S) share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Novonesis (Novozymes A/S)?
Analysts are divided on their view about Novonesis (Novozymes A/S) share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novonesis (Novozymes A/S) is a Sell and believe this share price will rise from its current level to --.
-
What Is Novonesis (Novozymes A/S)'s Price Target?
The price target for Novonesis (Novozymes A/S) over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVZMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novonesis (Novozymes A/S) is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NVZMY?
You can purchase shares of Novonesis (Novozymes A/S) via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novonesis (Novozymes A/S) shares.
-
What Is The Novonesis (Novozymes A/S) Share Price Today?
Novonesis (Novozymes A/S) was last trading at $59.77 per share. This represents the most recent stock quote for Novonesis (Novozymes A/S). Yesterday, Novonesis (Novozymes A/S) closed at $59.77 per share.
-
How To Buy Novonesis (Novozymes A/S) Stock Online?
In order to purchase Novonesis (Novozymes A/S) stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NVZMY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVZMY
Sector
P/E ratio
42.46x
18.55x
PEG ratio
0.45x
-0.03x
P/B ratio
2.46x
1.73x
Price / LTM sales
5.93x
1.53x
Growth Metrics
NVZMY
Sector
Revenue growth
10.81%
3.23%
Earnings growth
52.61%
--
Revenue (5-year growth)
16.97%
4.13%
Earnings forecast
--
$0.02
Profitability
NVZMY
Sector
Profitability FY 2025
$2.2B
--
Return on invested capital
4.28%
-10.88%
Return on assets
3.56%
-12.47%
Return on equity
5.31%
-11.42%
Earnings Date
Last Earnings Date
Feb
25
Next Earnings Date
Aug
20
Estimated Next Earnings Date
May
27
Balance Sheet
NVZMY
Sector
Total cash
$347.2M
$2.6M
Short term investments
$4.2M
$199.8K
Total assets
$20.5B
$16.4M
Long term debt
$1.5B
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
